Pfizer Stock News

The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP on Thursday. "We will have to get used to the fact that we will have to live with the virus for the next 10 years," said Ugur Sahin, whose company developed the first mRNA vaccine against the virus with Pfizer.

Ottawa, Feb 18 (IANS) Canada approved the Novavax Covid-19 vaccine for people aged 18 and over on Thursday, making it the fifth Covid-19 vaccine authorized in the country after AstraZeneca, Moderna, Pfizer and Johnson and Johnson. Health Canada said in a news release the vaccine is 90 per cent effective at preventing symptomatic Covid-19 and […] The post Canada approves Novavax Covid vaccine for adults appeared first on Buziness Bytes .

Pfizer Inc (NYSE: PFE ) / BioNTech SE''s (NASDAQ: BNTX ) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process, BioNTech Chief Executive Ugur Sahin told Germany''s Bild . Once the vaccine is ready, the company would assess … Full story available on Benzinga.com

OTTAWA, Feb. 17 (Xinhua) -- Canada approved the Novavax COVID-19 vaccine for people aged 18 and over on Thursday, making it the fifth COVID-19 vaccine authorized in the country after AstraZeneca, Moderna, Pfizer and Johnson and Johnson. Health Canada said in a news release the vaccine is 90 percent effective at preventing symptomatic COVID-19 and 100 percent effective at preventing severe disease. While a

"Pfizer tried to save the day with its MPP license and created a narrative about sharing technology," said Burcu Kilic of Public Citizen.

Novavax now joins Pfizer, Moderna, AstraZeneca and Johnson and Johnson as vaccine makers that have COVID-19 jabs approved for use in Canada.

Novavax now joins Pfizer, Moderna, AstraZeneca and Johnson and Johnson as vaccine makers that have COVID-19 jabs approved for use in Canada.

Macy''s Inc (NYSE: M ) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors. Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), BioNTech SE - ADR (NASDAQ: BNTX ), Novavax, Inc. (NASDAQ: … Full story available on Benzinga.com

Russia has expelled deputy U.S. ambassador Bartle Gorman and Washington will respond to the move, the RIA news agency cited the U.S. embassy in Moscow as saying on Thursday. It… Read more » The post Russia Expels Deputy U.S. Ambassador, Washington to Respond appeared first on Hamodia . In related news: Lebanon Pulled Into War With Islamic State Group Al-Qaida’s No. 2 Leader Killed In U.S. Strike on Yemen Report: U.K. Ready to Pay Up to €40B to Leave EU Trump to Tell Davos Forum He Won’t Tolerate Trade Abuses, IP Theft Britain Gets Ready for Roll-Out of Pfizer’s COVID-19 Vaccine This Week

FRANKFURT: The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP Thursday, as the company works on an Omicron-specific shot. "We will have to get used to the fact that we will have to live with the virus for the next 10 years," said Ugur Sahin, whose company developed the first mRNA vaccine against the virus with US pharma giant Pfizer. As the surge of cases due to the spread of the more transmissible Omicron variant of the virus seemed to be receding in Europe, Sahin said it would not be the last virus wave. New virus variants were inevitable "because the virus will mutate further", he said, potentially leading to new flare-ups in cases. But the world was "entering a phase where society is getting a better understanding on how to deal with the virus," Sahin said. BioNTech to ship mobile Covid vaccine labs to Africa "We are always learning more and are becoming better prepared," the BioNTech boss said.

JOHANNESBURG — South Africa’s health regulator SAHPRA said on Thursday that it had authorized use of Merck’s COVID-19 treatment pill molnupiravir. SAHPRA added in a statement that Pfizer had submitted an application for its COVID-19 pill, Paxlovid, which was under consideration. “The authorisation of molnupiravir for compassionate use offers further therapy in the fight against […]

DaVita (DVA) said a study suggested that dialysis patients who received Johnson & Johnson''s (JNJ) adenovirus vector-based COVID-19 vaccine were found to have similar rates of…

Paxlovid is the decisive factor, and Comirnaty''s bound to help too.

Doctors Group Demands Investigation Into Sudden Increase In Young Male Deaths In UK Authored by Owen Evans via The Epoch Times, A group of UK doctors, scientists, economists, psychologists, and other academic experts have called for an immediate investigation into the increasing death rate amongst 15- to 19-year-old males. The organisation HART, set up to share concerns about policy and guidance recommendations relating to the COVID-19 pandemic, has written to the British government over a rise in deaths in young males. To HART, the concern is that this time period coincides with the rollout of vaccinations to this age group, who are known to be at an increased risk of myocarditis (heart inflammation), especially after the second dose. Rising Death Rate As part of a judicial review at the High Court in January, the Office for National Statistics (ONS), confirmed that there had been a rise in the death rate for adolescent males over the last eight months, compared to the same time period of 2015–2019.

Pfizer''s billion-dollar mRNA vaccine could be just the beginning.